Global Insulin Market 2017: Focus on Insulin Delivery Devices - Market Outlook 2022 Approval of Glargine Basaglar - The First Biosimilar Insulin in the US - Research and Markets

DUBLIN, Mar. 8, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Insulin Market: Focus on Insulin Delivery Devices - Market Outlook 2022" report to their offering.

Growth of the global insulin market is propelled by increasing prevalence diabetes, rise in geriatric population, growing obese population, propagation of diabetes management awareness and government impetus. Major factors restraining growth of the market are high cost of insulin, insurance coverage issue, high competition and stringent regulatory pressure.

The report is segmented on the basis of insulin delivery devices market such as syringes, vials, insulin pumps, etc. Market analysis for these devices is provided for current as well as forecasted period.

Furthermore, insulin therapy market assessment is done across major markets such as Europe, North America and China. In-depth analysis of insulin therapy in aforementioned regions is done on the basis of overall insulin market size and market share by treatment option.

Leading industry players operating in the global insulin therapy market include Novo Nordisk, Sanofi Aventis, Eli Lilly and Company; and Merck & Co. These industry players are profiled herein based on attributes such as business overview, product segments, financial and business strategies.

The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics.

Global Insulin Market Dynamics

Industry Trends & Developments

• Dominance of Modern and New-Generation Insulin
• Advent of Intelligent Insulin Pens
• Sensor-augmented Pump Therapy
• Approval of Glargine Basaglar - The First Biosimilar Insulin in the US

Growth Drivers

• Increasing Prevelance of Diabetes
• Rise in Geriatric Population
• Growing Obese Population
• Propogation of Diabetes Management Awareness
• Government Impetus

Challenges

• High Cost of Insulin
• Insurance Coverage issue
• High Competition
• Regulatory Pressure

Companies Mentioned

• Eli Lilly and Company
• Merck & Co.
• Novo Nordisk
• Sanofi Aventis

For more information about this report visit http://www.researchandmarkets.com/research/sppv77/global_insulin

Media Contact:

Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]